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Intranasal nanoemulsion adjuvant vaccine prevents allergic reactions from milk allergy without eliminating serum IgE Jessica J. O. Konek, PhD, Jeffery J. Landers, BS, Katarzyna W. Janczak, MS, Tiffanie D. Totten, Hayley K. Lindsey, and James R. Baker, Jr, MD FAAAAI; Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, MI. RATIONALE: Most immunotherapies for food allergy require prolonged treatment protocols and do not often lead to long-term allergy protection, which is typically lost within weeks of stopping therapy. Our group has developed an intranasal (IN) nanoemulsion adjuvant that redirects allergen-specific Th2 responses towards Th1 and Th17 and protects from allergen challenge after only four administrations. Here, we investigate the ability of this technology to modulate allergy in a long-term murine model of cow's milk allergy. METHODS: Mice were sensitized intraperitoneally with 2 doses of bovine casein protein, administered with aluminum hydroxide. Six weeks after sensitization, mice received four, monthly IN immunizations with nanoemulsion formulated with casein. The mice were subsequently challenged with allergen at 4, 10 and 16 weeks after the final vaccine dose. Control animals were identically sensitized but received IN allergen alone in saline. RESULTS: As compared to control, IN vaccine blocked physiological responses to allergen challenge, and protection persisted for at least 16 weeks. The vaccine modulated casein-specific Th2 immunity and induced Th1 and Th17 cytokines as well as IL-10. There was also a reduction of mast cell numbers in the small intestine. However, while immunized animals showed significantly decreased Th2 cytokine responses, caseinspecific IgE remained elevated in the serum. CONCLUSIONS: IN nanoemulsion vaccine induces long-term protection from anaphylaxis and significantly modulates Th2 immunity despite the persistence of IgE. The sustained unresponsiveness suggests that the nanoemulsion vaccine is changing the allergic phenotype in a manner different from traditional desensitization. data in 40 subjects demonstrated for the first time that preschool peanut oral immunotherapy (P-OIT) was safe, with predominantly mild symptoms reported and only one case of anaphylaxis requiring epinephrine. We sought to examine whether these findings would hold true in the real world, outside a research setting. METHODS: As part of a Canada-wide quality improvement project, academic and community allergists administered P-OIT to children who had 1) a positive SPT (> _3mm) or sIgE (> _0.35kU/L) and a history of reaction, or 2) no ingestion history and a positive sIgE (> _5kU/L). Patients had bi-weekly clinic visits for updosing, and consumed the dose daily at home between visits, up to a maintenance dose of 300 milligramsover a target of 16 weeks. Symptoms were classified using the World Allergy Organization Subcutaneous Immunotherapy Reaction Grading System (1 mildest, 5 most severe). RESULTS: Of 220 patients who started P-OIT in 2017-18, 195 completed buildup, and 25 dropped out (11.4%). Twenty-one (84%) dropouts experienced reactions. Of all participants, experienced reactions during buildup(average 2.3 reactions per patient).53% grade 1, 43% grade 2, 1.2% grade 3, and 2.4% grade 4. Nine patients (4.1%) received epinephrine(4 inclinic, 5 at-home), representing 1.76% of reactions (9/512). CONCLUSIONS: We are the first to describe preschool P-OIT in a realworld multi-center setting. We confirm with a much larger sample that the treatment is safe, as symptoms experienced were generally mild and fewreactions received epinephrine. These data support availability of preschool peanut OIT outside research.
